Hydra Biosciences Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Hydra Biosciences Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013968
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:18
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Hydra Biosciences Inc (Hydra) is a biopharmaceutical company that develops novel drugs. The company’s pipeline candidate HX-100 is developed to treat diabetic neuropathy and allergic asthma. It offers other drugs for the therapeutic areas including inflammation, pain, renal, anxiety and pulmonary disease. Hydra provides products for dermatological disorders such as pruritus and psoriasis. The company develops transient receptor potential that offers drug discovery opportunities in multiple areas of human disease. Its screening platforms and integrated pharmacology and chemistry infrastructure enable the company to identify and develop drug candidates for various health conditions. The company’s ion channels provides the potential to develop selective and safer ion channel drugs. Hydra is headquartered in Cambridge, Massachusetts, the US.

Hydra Biosciences Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Hydra Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Hydra Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Hydra Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Hydra Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Hydra Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Hydra Biosciences Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Hydra Biosciences Raises USD10.5 Million in Venture Financing 10
Partnerships 11
Hydra Biosciences Enters Into R&D Agreement With Boehringer Ingelheim 11
Zalicus And Hydra Biosciences Enter Into Partnership To Develop Ion Channel Product Candidates For Treatment Of Pain 12
Licensing Agreements 13
Hydra Biosciences Enters into Licensing Agreement with Boehringer Ingelheim 13
Hydra Biosciences Inc – Key Competitors 14
Hydra Biosciences Inc – Key Employees 15
Hydra Biosciences Inc – Locations And Subsidiaries 16
Head Office 16
Recent Developments 17
Product News 17
01/06/2016: Hydra Biosciences to Present at the 8th Annual Biotech Showcase Conference in San Francisco on Jan. 11 17
Appendix 18
Methodology 18
About GlobalData 18
Contact Us 18
Disclaimer 18

List of Tables
Hydra Biosciences Inc, Pharmaceuticals & Healthcare, Key Facts 2
Hydra Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Hydra Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Hydra Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Hydra Biosciences Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Hydra Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Hydra Biosciences Raises USD10.5 Million in Venture Financing 10
Hydra Biosciences Enters Into R&D Agreement With Boehringer Ingelheim 11
Zalicus And Hydra Biosciences Enter Into Partnership To Develop Ion Channel Product Candidates For Treatment Of Pain 12
Hydra Biosciences Enters into Licensing Agreement with Boehringer Ingelheim 13
Hydra Biosciences Inc, Key Competitors 14
Hydra Biosciences Inc, Key Employees 15

★海外企業調査レポート[Hydra Biosciences Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Anthem Inc (ANTM)-製薬・医療分野:企業M&A・提携分析
    Summary Anthem Inc (Anthem), formerly WellPoint Inc, is a health benefits company. It offers several managed healthcare related products and related administrative services. It also provides various specialty and insurance products and services including radiology benefit management, dental, life an …
  • Accelya Kale Solutions Limited (ACCELYA):企業の財務・戦略的SWOT分析
    Accelya Kale Solutions Limited (ACCELYA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Franz Haniel & Cie. GmbH:企業の戦略的SWOT分析
    Franz Haniel & Cie. GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Xenon Pharmaceuticals Inc (XENE):製薬・医療:M&Aディール及び事業提携情報
    Summary Xenon Pharmaceuticals Inc (Xenon), formerly Xenon Genetics Inc, is a biopharmaceutical company that discovers and develops therapeutics for patients suffering with neurological disorders. The company's pipeline products include XEN1101, XEN901, XEN007 and GDC-0310. It discovers various valid …
  • Qatar Airways Group Q.C.S.C.:企業の戦略・SWOT・財務分析
    Qatar Airways Group Q.C.S.C. - Strategy, SWOT and Corporate Finance Report Summary Qatar Airways Group Q.C.S.C. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • HORNBACH-Baumarkt-AG (HBM):企業の財務・戦略的SWOT分析
    HORNBACH-Baumarkt-AG (HBM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Exelixis Inc (EXEL):製薬・医療:M&Aディール及び事業提携情報
    Summary Exelixis Inc (Exelixis) is a biopharmaceutical company that focuses on the development and commercialization of small molecule therapies for the treatment of cancer. The company has three product candidates: Cometriq (Cabozantinib), an inhibitor of multiple receptor tyrosine kinases; Cabomet …
  • Aptiv Plc. (APTV):企業の財務・戦略的SWOT分析
    Aptiv Plc. (APTV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • MyoKardia Inc (MYOK):企業の財務・戦略的SWOT分析
    MyoKardia Inc (MYOK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • HNA Group Co Ltd:企業のM&A・事業提携・投資動向
    HNA Group Co Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's HNA Group Co Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), dives …
  • PrIME Biologics Pte Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary PrIME Biologics Pte Ltd (PrIME Biologics) is a biotechnology company that develops and manufactures plasma products for human use. The company uses Preparative Isolation by Membrane Electrophoresis ((PrIME) technology, a disposable, fully-scalable and modular manufacturing process, to manufa …
  • Credit Suisse Group AG:戦略・SWOT・企業財務分析
    Credit Suisse Group AG - Strategy, SWOT and Corporate Finance Report Summary Credit Suisse Group AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Yihai International Holding Ltd (1579):企業の財務・戦略的SWOT分析
    Yihai International Holding Ltd (1579) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • B. Braun Melsungen AG:企業の戦略的SWOT分析
    B. Braun Melsungen AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Massachusetts Mutual Life Insurance Company:企業のM&A・事業提携・投資動向
    Massachusetts Mutual Life Insurance Company - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Massachusetts Mutual Life Insurance Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, det …
  • e-Therapeutics Plc (ETX):企業の財務・戦略的SWOT分析
    e-Therapeutics Plc (ETX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • RentPath, LLC:企業の戦略・SWOT・財務情報
    RentPath, LLC - Strategy, SWOT and Corporate Finance Report Summary RentPath, LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Porton Pharma Solutions Ltd (300363):企業の財務・戦略的SWOT分析
    Summary Porton Pharma Solutions Ltd (Porton) is involved in the supply of intermediate drugs and active pharmaceutical ingredients. The company provides custom and contract chemical development, and contract manufacturing services. It is also involved in providing research and development and produc …
  • TETRA Technologies Inc Oil & Gas Exploration and Production Operations and Cost Analysis – 2017
    TETRA Technologies Inc Oil & Gas Exploration and Production Operations and Cost Analysis - 2017 Summary TETRA Technologies Inc (TETRA) is an oil and gas company that offers completion fluids and associated products and services. The company’s services comprise compression services, fluid, filtration …
  • Toyota Motor Corp (7203):企業の財務・戦略的SWOT分析
    Toyota Motor Corp (7203) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆